Arcturus Therapeutics Holdings Future Growth
Future criteria checks 5/6
Arcturus Therapeutics Holdings is forecast to grow earnings and revenue by 68.2% and 33% per annum respectively. EPS is expected to grow by 68.3% per annum. Return on equity is forecast to be -157.5% in 3 years.
Key information
68.2%
Earnings growth rate
68.3%
EPS growth rate
| Biotechs earnings growth | 29.7% |
| Revenue growth rate | 33.0% |
| Future return on equity | -157.5% |
| Analyst coverage | Good |
| Last updated | 04 Sep 2024 |
Recent future growth updates
Recent updates
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06
High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 355 | 46 | -151 | N/A | 8 |
| 12/31/2025 | 236 | -48 | -192 | N/A | 9 |
| 12/31/2024 | 189 | -75 | N/A | N/A | 10 |
| 6/30/2024 | 164 | -72 | -71 | -69 | N/A |
| 3/31/2024 | 125 | -107 | 10 | 12 | N/A |
| 12/31/2023 | 167 | -30 | -21 | -18 | N/A |
| 9/30/2023 | 296 | 99 | 137 | 143 | N/A |
| 6/30/2023 | 264 | 80 | 126 | 133 | N/A |
| 3/31/2023 | 281 | 111 | 39 | 45 | N/A |
| 12/31/2022 | 206 | 9 | 24 | 32 | N/A |
| 9/30/2022 | 52 | -147 | -176 | -171 | N/A |
| 6/30/2022 | 41 | -165 | -150 | -145 | N/A |
| 3/31/2022 | 15 | -198 | -147 | -141 | N/A |
| 12/31/2021 | 12 | -204 | -138 | -135 | N/A |
| 9/30/2021 | 9 | -196 | -102 | -99 | N/A |
| 6/30/2021 | 9 | -163 | -100 | -98 | N/A |
| 3/31/2021 | 9 | -119 | -76 | -74 | N/A |
| 12/31/2020 | 10 | -72 | -45 | -43 | N/A |
| 9/30/2020 | 10 | -52 | -45 | -44 | N/A |
| 6/30/2020 | 11 | -38 | -32 | -31 | N/A |
| 3/31/2020 | 19 | -29 | -14 | -13 | N/A |
| 12/31/2019 | 21 | -26 | -7 | -6 | N/A |
| 9/30/2019 | 25 | -16 | -5 | -5 | N/A |
| 6/30/2019 | 26 | -13 | -9 | -9 | N/A |
| 3/31/2019 | 18 | -22 | -27 | -26 | N/A |
| 12/31/2018 | 16 | -22 | -22 | -21 | N/A |
| 9/30/2018 | 10 | -26 | -11 | -10 | N/A |
| 6/30/2018 | 10 | -25 | -6 | -5 | N/A |
| 3/31/2018 | 12 | -16 | N/A | 1 | N/A |
| 12/31/2017 | 13 | -11 | N/A | 0 | N/A |
| 12/31/2016 | 20 | -2 | N/A | -3 | N/A |
| 12/31/2015 | 6 | -2 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: ARCT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARCT is expected to become profitable in the next 3 years.
Revenue vs Market: ARCT's revenue (33% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: ARCT's revenue (33% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARCT is forecast to be unprofitable in 3 years.